Sweden's BioGaia Q3 sales rise on pediatrics and adult health segments
Sweden's BioGaia Q3 sales rise on pediatrics and adult health segments
Overview
Sweden probiotic products maker's Q3 net sales rose 23% yr/yr excluding currency effects
Adjusted EPS for Q3 increased yr/yr
Growth driven by both Pediatrics and Adult Health segments across key markets
Outlook
Company says it will focus on growth and profitability in the final quarter
BioGaia plans continued investment in science-based innovation and market expansion
Company to roll out new Colus product in UK, with phased launch in other markets
Result Drivers
MARKETING AND DISTRIBUTION - Increased consumer and medical marketing in the Americas and expanded distribution in EMEA contributed to sales growth
ADULT HEALTH SEGMENT - Strong sales growth in Adult Health segment, especially for Prodentis product
ORDER TIMING - EMEA sales benefited from orders shifted forward from Q4
Company press release: ID:nWkr16B1gJ
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | SEK 400.40 mln | SEK 386.35 mln (2 Analysts) |
Q3 Adjusted EPS |
| SEK 1.09 |
|
Q3 Net Income |
| SEK 110.20 mln |
|
Q3 EBIT | Beat | SEK 132.60 mln | SEK 125.80 mln (2 Analysts) |
Q3 EBIT Margin |
| 33.00% |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Biogaia AB is SEK160.00, about 29% above its October 21 closing price of SEK124.00
The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 27 three months ago
Reuters Recommended Reads
Oct 22 - Sweden's Sedana Medical Q3 sales rise as growth returns
Oct 22 - Sweden's Careium Q3 sales rise 21.6%, margin improves
Oct 22 - Sweden's Bactiguard Q3 revenue rises on partnership with Becton, Dickinson & Company
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)